Further evidence for the association between CD103 and poorer clinical outcome in cancer was demonstrated in TCGA data showing high ITGAE expression was associated with reduced survival in primary cutaneous melanoma, breast carcinoma, kidney chromophobe cancer, renal cell carcinoma, lower grade glioma and adrenocortical carcinoma. This evidence concerns the gene ITGAE and glioma.